Several authors have highlighted the importance of a good response to chemotherapy in multiple myeloma (MM), especially in first line. We assessed whether a deep response is prognostic for overall survival (OS) independent of treatment, treatment line and patient/disease characteristics based on a Nordic RWE dataset of 3000 patients. Multivariate cox-regressions show that in the first four lines of treatment, response is an independent prognostic factor for OS. Hence, treatment response seems to play an important role for OS irrespective of treatment line. Because of this, it is important to closely monitor the response of the given treatment. For development of new treatments, response should also be an important surrogate marker for overall survival for instance in phase II trials. This research was presented at European Hematology Association conference in June 2015.

If you are interested in a copy of the poster, in assessing weather response is an applicable surrogate marker for overall survival for your hematology product, please contact Bart (Bart.Heeg@ingress-health.com) or Susanne (Susanne.Brandt@ingress-health.com).